Format

Send to

Choose Destination
See comment in PubMed Commons below
Health Policy. 2004 Aug;69(2):151-7.

The cerivastatin withdrawal crisis: a "post-mortem" analysis.

Author information

1
National Center of Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy. mmaggini@iss.it

Abstract

In August 2001, cerivastatin was removed from European and USA markets because of a higher risk of rhabdomyolysis associated with its use in comparison with other statins. The objective of this study was to compare cholesterol-lowering drug use in Italy before and after the withdrawal of cerivastatin from the market, and to evaluate if the withdrawal influenced patients compliance and physicians prescribing habits. After August 2001, 48% of cerivastatin users discontinued any statin treatment. The major risk factor for discontinuation was a concomitant use of fibrate during the first 7 months of 2001 (OR = 2.3; 95% CI = -2.9). Comparing the discontinuation of statin therapy between 2001 and 2000 we can estimate that there was a 5% increase, corresponding to about 200,000 patients, who discontinued statin therapy during autumn 2001 because of cerivastatin emergency.

PMID:
15212862
DOI:
10.1016/j.healthpol.2004.04.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center